Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data Prime Medicine, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2022
FY2022
FY2023
FY2024
FY2025
Revenue
5.21
0
0
0
2.98
4.63
Research and development
2.98
70.6
86.7
148
155
161
General and administrative
3.16
13.9
29.8
43.4
50.2
52.3
Operating expenses
6.14
84.5
117
205
205
213
Operating income
-0.93
-84.5
-117
-205
-202
-208
Interest income
2.81
3.52
4.15
Other non-operating income
-0.61
-81.4
-6.23
6.38
6.59
7.21
Income tax
1.87
-0.49
-0.95
-0.28
0
0
Net income
-3.41
-165
-122
-198
-196
-201
EBITDA
-0.89
-83.9
-114
-200
-196
-201
EPS, basic
-1.91
-14.19
-4.19
-2.18
-1.65
-1.35
EPS, diluted
-1.91
-14.19
-4.19
-2.18
-1.65
-1.35
Shares, basic (weighted)
2.64
13
33.9
91
119
149
Shares, diluted (weighted)
2.64
13
33.9
91
119
149
Balance sheet
FY2020
FY2022
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
37
185
188
41.6
182
63
Short-term investments
68.2
98.5
115
Other current assets
0.96
0.25
2.25
14.7
0.67
Total current assets
271
297
143
212
181
Property, plant and equipment
4.93
19
22.7
24.4
20.6
Lease right-of-use assets
10.7
29.5
13.9
47.2
126
Other non-current assets
2.47
1.65
0.78
0
1
Total assets
302
360
194
298
343
Accounts payable
1.44
4.33
19.5
11.4
8.89
Accrued liabilities
37.2
10.7
14.1
15.9
12.6
Deferred revenue
0
7.09
7.82
Total current liabilities
58
26.7
56.4
38
37.4
Lease liabilities
3.07
17.1
4.36
37.2
108
Total liabilities
62.3
44
60.8
144
222
Paid-in capital
15.2
610
624
840
1,009
Retained earnings
-171
-293
-491
-687
-888
Other comprehensive income
-0.03
-0.38
-0.02
0
0.08
Shareholders' equity
2.34
-156
316
133
153
121
Total equity
2.34
-156
316
133
153
121
Total liabilities and equity
302
360
194
298
343
Shares outstanding
32.4
97.2
97.4
131
181
Cash flow statement
FY2020
FY2022
FY2022
FY2023
FY2024
FY2025
Net income
-3.41
-165
-122
-198
-196
-201
Depreciation and amortization
0.04
0.57
2.22
4.65
6.13
7.32
Stock-based compensation
0.39
1.75
6.46
13.9
26.1
29.3
Deferred income tax
1.87
-0.62
-0.96
-0.28
0
Change in payables
0.25
1.19
2.46
9.14
-5.26
1
Cash from operations
-5.54
-34.1
-132
-165
-123
-163
Capital expenditures
-0.64
-4.15
-16.1
-8.72
-7.29
-4.53
Purchases of investments
0
-82
-123
-105
-129
-205
Cash from investing
-1.06
-73.6
-47.1
18.7
68.5
-109
Stock issued
0
0
0.22
0
38.1
0
Cash from financing
34.9
269
181
0.66
196
152
Net change in cash
28.3
162
2.57
-146
141
-120
Free cash flow
-6.18
-38.2
-148
-174
-130
-167
Income taxes paid
0
0
0.14
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $2.90 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-472.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-75.4%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
55.3%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 5y
-2.3%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-21.1%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-27.4%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
120.1%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
15.2%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-1.7%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
25.4%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
63.7%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
124.0%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
3.05x
Current assets / current liabilities.
Quick ratio
3.00x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
3.00x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$0.89
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.88
Cash from operations / diluted weighted shares.
Book value per share
$0.22
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
13.2x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
13.2x
Market cap / tangible book value, when positive.
FCF yield
-29.8%
Free cash flow / market cap.
Earnings yield
-35.7%
Net income / market cap (the inverse of P/E).
What was Prime Medicine, Inc.'s revenue in fiscal 2025?
Prime Medicine, Inc. reported revenue of $4.6M for fiscal 2025, 55.3% higher than the year before.
Was Prime Medicine, Inc. profitable in fiscal 2025?
No. It reported a net loss of $201.1M.
How much free cash flow did Prime Medicine, Inc. generate in fiscal 2025?
Cash from operations of $162.6M minus capital expenditures of $4.5M left free cash flow of -$167.1M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.